LAUSR

0123456789();: suggests that pembrolizumab can eradicate micrometastatic disease, which might ultimately translate into an overall survival benefit. Pembrolizumab was associated with mostly low-grade adverse events, with grade 3–4 toxicities in only 16% of patients (compared with 4% with placebo) and no treatmentrelated deaths. Nevertheless, ~90% of the 118 pembrolizumab-related endocrinopathies required longterm hormone replacement, which is notable in this setting. The results of the first interim analysis of KEYNOTE-716 led to full FDA approval of pembrolizumab for this patient population in December 2021. However, distant metastasis-free survival, overall survival and quality-of-life data will be needed to establish the true clinical benefit of adjuvant pembrolizumab.